Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2024 07:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.